{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:07:53Z","timestamp":1761948473752},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.intimp.2019.01.014","type":"journal-article","created":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T22:19:18Z","timestamp":1547590758000},"page":"213-217","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Highly aggressive plasmablastic neoplasms in patients with rheumatoid arthritis treated with methotrexate"],"prefix":"10.1016","volume":"68","author":[{"given":"Rie","family":"Tabata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiharu","family":"Tabata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Uesugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2019.01.014_bb0005","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ejh.12116","article-title":"Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression","volume":"91","author":"Ichikawa","year":"2013","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.intimp.2019.01.014_bb0010","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.5858\/arpa.2016-0232-RA","article-title":"Plasmablastic lymphoma. A review of clinicopathologic features and differential diagnosis","volume":"140","author":"Harmon","year":"2016","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.intimp.2019.01.014_bb0015","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/modpathol.3800355","article-title":"Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles","volume":"18","author":"Vega","year":"2005","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.intimp.2019.01.014_bb0020","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/ajh.21250","article-title":"HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases","volume":"83","author":"Castillo","year":"2008","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.intimp.2019.01.014_bb0025","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.3892\/or.2015.3808","article-title":"Human immunodeficiency virus-negative plasmablastic lymphoma: a comprehensive analysis of 114 cases","volume":"33","author":"Liu","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.intimp.2019.01.014_bb0030","article-title":"Plasmablastic lymphoma: review of 60 Chinese cases and prognosis analysis","volume":"96","author":"Han","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.intimp.2019.01.014_bb0035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12032-016-0803-3","article-title":"Plasma cell maturity as a predictor of prognosis in multiple myeloma","volume":"33","author":"Iriyama","year":"2016","journal-title":"Med. Oncol."},{"key":"10.1016\/j.intimp.2019.01.014_bb0040","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1309\/BVT4-YP41-LCV2-5GT0","article-title":"Cyclin D1 overexpression in multiple myeloma. A morphologic, immunohistochemical, and in situ hybridization study of 71 paraffin-embedded bone marrow biopsy specimens","volume":"116","author":"Athanasiou","year":"2001","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.intimp.2019.01.014_bb0045","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1080\/08998280.2017.11929581","article-title":"Plasma cell myeloma with lymphoplasmacytic morphology and cyclin D1 expression: an uncommon variant","volume":"30","author":"Hale","year":"2017","journal-title":"Proc. (Baylor Univ. Med. Cent.)"},{"key":"10.1016\/j.intimp.2019.01.014_bb0050","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00277-017-3125-4","article-title":"High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma","volume":"96","author":"Wang","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.intimp.2019.01.014_bb0055","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/cas.13249","article-title":"Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: comparison of diffuse large B-cell lymphoma and classical Hodgkin lymphoma types","volume":"108","author":"Gion","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.intimp.2019.01.014_bb0060","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.prp.2006.05.007","article-title":"Methtrexate-associated lymphoproliferative disorders. A clinicopathological study of 13 Japanese cases","volume":"202","author":"Kojima","year":"2006","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.intimp.2019.01.014_bb0065","series-title":"World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"350","article-title":"Other iatrogenic immunodeficiency-associated lymphoproliferative disorders","author":"Gaulard","year":"2008"},{"key":"10.1016\/j.intimp.2019.01.014_bb0070","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3109\/10428194.2011.625101","article-title":"Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis","volume":"53","author":"Tokuhira","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.intimp.2019.01.014_bb0075","first-page":"322","article-title":"Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication","volume":"34","author":"Hoshida","year":"2007","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.intimp.2019.01.014_bb0080","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2019.01.014_bb0085","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000287","article-title":"Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures","volume":"2","author":"Kremer","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.intimp.2019.01.014_bb0090","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1136\/annrheumdis-2017-212537","article-title":"Methotrexate limits inflammation through an A20-dependent cross-tolerance mechanism","volume":"77","author":"Municio","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2019.01.014_bb0095","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1615\/CritRevImmunol.v32.i4.40","article-title":"Immune functions of serum amyloid A","volume":"32","author":"Eklund","year":"2012","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.intimp.2019.01.014_bb0100","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.4049\/jimmunol.1401190","article-title":"Cutting edge: circulating plasmablasts induce the differentiation of human T follicular helper cells via IL-6 production","volume":"194","author":"Chavele","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2019.01.014_bb0105","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s10020-018-0047-0","article-title":"Serum amyloid A - a review","volume":"24","author":"Sack","year":"2018","journal-title":"Mol. Med."},{"key":"10.1016\/j.intimp.2019.01.014_bb0110","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1111\/ajd.12479","article-title":"Uncommon cutaneous lymphoproliferative disorders in two patients with rheumatoid arthritis","volume":"58","author":"Carroll","year":"2017","journal-title":"Australas. J. Dermatol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576918313043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576918313043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T22:29:00Z","timestamp":1550010540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576918313043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":22,"alternative-id":["S1567576918313043"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2019.01.014","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Highly aggressive plasmablastic neoplasms in patients with rheumatoid arthritis treated with methotrexate","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2019.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}